Evidence map›Paper›PMID 37406590›Full record

ArticleEBioMedicine2023

B-cell immunity and vaccine induced antibody protection reveal the inefficacy of current vaccination schedule in infants with perinatal HIV-infection in Mozambique, Africa.

Nicola Cotugno, Suresh Pallikkuth, Marco Sanna, Vinh Dinh, Lesley de Armas, Stefano Rinaldi, Sheldon Davis, Giulia Linardos, Giuseppe Rubens Pascucci, Rajendra Pahwa and 6 more

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Accelerated CD8iScience · 2024
    Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Nicola CotugnoClinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.
Suresh PallikkuthDepartment of Microbiology and Immunology, Miami Center for AIDS Research, Miller School of Medicine, University of Miami, Miami, United States.
Marco SannaClinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.
Vinh DinhDepartment of Microbiology and Immunology, Miami Center for AIDS Research, Miller School of Medicine, University of Miami, Miami, United States.
Lesley de ArmasDepartment of Microbiology and Immunology, Miami Center for AIDS Research, Miller School of Medicine, University of Miami, Miami, United States.
Stefano RinaldiDepartment of Microbiology and Immunology, Miami Center for AIDS Research, Miller School of Medicine, University of Miami, Miami, United States.
Sheldon DavisDepartment of Microbiology and Immunology, Miami Center for AIDS Research, Miller School of Medicine, University of Miami, Miami, United States.
Giulia LinardosMicrobiology and Diagnostic Immunology Unit, Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio, 4, Rome 00165, Italy.
Giuseppe Rubens PascucciClinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.
Rajendra PahwaDepartment of Microbiology and Immunology, Miami Center for AIDS Research, Miller School of Medicine, University of Miami, Miami, United States.
Nadia SitoeFundação Ariel Glaser Contra o SIDA Pediatrico, Maputo, Mozambique.
Paula VazInstituto Nacional de Saúde, Marracuene, Maputo Province, Mozambique.
Paolo RossiChair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", Rome 00133, Italy; Chair of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy.
Maria Grazia LainFundação Ariel Glaser Contra o SIDA Pediatrico, Maputo, Mozambique.
Paolo PalmaClinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome 00165, Italy; Chair of Pediatrics, Department of Systems Medicine, University of Rome "Tor Vergata", Rome 00133, Italy. Electronic address: paolo.palma@opbg.net.
Savita PahwaDepartment of Microbiology and Immunology, Miami Center for AIDS Research, Miller School of Medicine, University of Miami, Miami, United States. Electronic address: spahwa@med.miami.edu.
University of Miami · USUniversity of Rome Tor Vergata · ITFundação Ariel Glaser Contra o SIDA Pediátrico · MZBambino Gesù Children's Hospital · ITInstituto Nacional de Saúde · MZ

Funding

University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Immunity and HIV persistence in perinatal HIV infectionR01AI127347 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI PAHWA, SAVITA · 2016 to 2020
$3.3M
Predoctoral Training in Translational ImmunologyT32AI162624 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Thomas R Malek · 2022 to 2026
$894k
NIAID NIH HHS P30 AI073961NIAID NIH HHS R01 AI127347NIAID NIH HHS T32 AI162624
6 · The paper itself

Abstract

backgroundDespite antiretroviral treatment (ART), immune dysfunction persists in children with perinatal HIV infection (HEI). Here we investigated the impact of HIV status on maternal antibody (Ab) passage, long-term vaccine induced immunity and B-cell maturation.

methods46 HIV Exposed Uninfected (HEU), 43 HEI, and 15 HIV unexposed uninfected (HUU) infants were vaccinated with 3 doses of DTaP-HepB-Hib-PCV10-OP at 2, 3, and 4 months at Matola Provincial Hospital, Maputo, Mozambique. Tetanus toxoid specific (TT) IgG, HIV Ab and B-cell phenotype characteristics were evaluated at entry, pre-ART, 5, 10, and 18 months in this longitudinal cohort study.

findingsBaseline (maternal) plasma TT Ab levels were significantly lower in HEI compared to both HEU and HUU and a faster decay of TT Ab was observed in HEI compared to HEU with significantly lower TT Ab levels at 10 and 18 months of age. TT unprotected (UP) (≤0.1 IU/mL) HEI showed higher HIV-RNA at entry and higher longitudinal HIV viremia (Area Under the Curve) compared to TT protected (P) HEI. A distinct HIV-Ab profile was found at entry in HEI compared to HEU. B-cell phenotype showed a B-cell perturbation in HEI vs HEU infants at entry (mean age 40.8 days) with lower transitional CD10+CD19+ B-cells and IgD+CD27- naive B-cells and an overall higher frequency of IgD-CD27- double negative B-cell subsets in HEI.

interpretationB-cell perturbation, presenting with higher double negative IgD-CD27- B-cells was observed in neonatal age and may play a major role in the B-cell exhaustion in HEI. The ability to maintain TT protective Ab titers over time is impaired in HEI with uncontrolled viral replication and the current vaccination schedule is insufficient to provide long-term protection against tetanus.

fundingThis work was supported by: NIH grant to SP (5R01AI127347-05); Children's Hospital Bambino Gesú (Ricerca corrente 2019) to NC, and Associazione Volontari Bambino Gesù to PP.

Indexed as

HIV InfectionsVaccinesAfricaAntibodiesAnti-Retroviral AgentsFemaleHumansLongitudinal StudiesMozambiquePregnancyVaccinationAntibodiesAnti-Retroviral AgentsVaccinesB-cell agingDouble negative B-cellsMemory B-CellsPediatric HIVTetanus responsesVaccine induced immunity

Identifiers

PMID37406590
PMCPMC10363429
OpenAlexW4382931629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.